自调节减弱了大鼠诱导的HCC中索拉芬尼抗性的作用
Yomna Elleithi1,2, Amal El-Gayar3, Mohamed N Amin3
1Biochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. yomnaelleithi@mans.edu.eg.
Cell death & disease
|August 16, 2024
概括
这项研究探讨了操纵自的方法,以克服肝细胞癌 (HCC) 中的索拉芬尼抗性. 自诱导剂和抑制剂都在降低药物耐药性和保护肝脏方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝细胞癌 (HCC) 是癌症死亡的主要原因,预后不佳.
- 索拉费尼布是先进的HCC的第一线治疗方法,由于获得的耐药性而面临限制.
- 瘤微环境 (TME) 和自在治疗耐药性中起着至关重要的作用.
研究的目的:
- 调查调节自对HCC索拉费尼布疗效的影响.
- 分析自诱导和抑制与索拉费尼布治疗结合的效果.
主要方法:
- 使用西方斑块,ELISA,免疫组织化学,流细胞测量和定量PCR来评估自,细胞亡和细胞周期.
- 进行了常规的生化和病理分析.
- 使用传输电子显微镜 (TEM) 进行超结构和自实体观测.
主要成果:
- 自诱导和抑制策略,当与sorafenib相结合时,显著降低了化疗耐药性.
- 在治疗组中观察到肝保护作用.
- 调节自证明了对克服索拉芬尼布耐药性的积极影响.
结论:
- 自在癌症中起着双重作用,支持在压力下生存,但也抑制了癌症发生.
- 控制自是一种增强癌症治疗的可行策略.
- 自抑制剂和诱导剂都是克服HCC中索拉芬尼抗性的有希望的候选者.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


